Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology
Anixa Biosciences (NASDAQ: ANIX) announced that its collaborator, Cleveland Clinic, has received a 'Decision to Grant' notice from the Japan Patent Office for a patent application on breast cancer vaccine technology. This extends the patent protection to Japan, in addition to existing U.S. and European patents. Anixa is the exclusive worldwide licensee of this technology.
The vaccine, currently in phase one clinical trials at Cleveland Clinic, targets α-lactalbumin, a breast-specific lactation protein present in certain breast cancers but not in normal aging tissues post-lactation. By activating the immune system against this 'retired' protein, the vaccine aims to provide preemptive protection against emerging breast tumors expressing α-lactalbumin.
- Received 'Decision to Grant' notice for Japanese patent on breast cancer vaccine technology
- Extended patent protection to Japan, in addition to U.S. and European patents
- Exclusive worldwide licensee of the breast cancer vaccine technology
- Phase one clinical trial of the vaccine ongoing at Cleveland Clinic
- None.
The grant of a Japanese patent for Anixa Biosciences' breast cancer vaccine technology represents a significant milestone in the field of oncology and immunotherapy. Patents play a important role in protecting intellectual property and provide a competitive edge to companies by preventing others from using their patented technology. This new patent extends the proprietary reach of the vaccine technology to Japan, adding to the U.S. and European patents already secured.
From a clinical perspective, the phase one trial being conducted at the Cleveland Clinic aims to evaluate the safety, tolerability and preliminary efficacy of this innovative vaccine. Given the unique mechanism of targeting a 'retired' protein, α-lactalbumin, present in certain breast cancers, this vaccine has the potential to offer a novel preventive approach against breast cancer. While phase one trials are primarily focused on safety, positive results could lead to further clinical development and eventual commercialization.
Investors should note that while the grant of the patent is a positive development, the clinical success of the vaccine is still uncertain and depends on upcoming trial results. However, securing intellectual property in multiple regions reduces competitive threats and positions Anixa favorably for future market opportunities.
The announcement of the Japanese patent for Anixa Biosciences' breast cancer vaccine technology could enhance the company's financial outlook. Patents are valuable assets that can lead to revenue generation through licensing deals, partnerships and potential market exclusivity. The extension of patent protection to Japan indicates the company's strategic approach to securing its intellectual property across major markets, which could attract more investors.
In terms of financial implications, the broader patent coverage may bolster investor confidence and potentially lead to a positive impact on Anixa's stock price. However, it is important to remain cautious as the vaccine is still in the early stages of clinical trials. Substantial financial rewards are contingent upon successful clinical outcomes and regulatory approvals, which could take several years to materialize.
Nonetheless, the patent grant signals progress in Anixa's development pipeline and strengthens its IP portfolio, which is a positive indicator for long-term growth prospects. Investors should keep an eye on upcoming trial data and any strategic partnerships that may arise from this development.
"This new Japanese patent extends the claims for this novel breast cancer vaccine technology to an additional geographic region, beyond the
The vaccine is currently being studied in a phase one clinical trial at Cleveland Clinic.
Anixa's breast cancer vaccine takes advantage of endogenously produced proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein is a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present in certain breast cancers. Activating the immune system against this "retired" protein provides preemptive immune protection against emerging breast tumors that express α-lactalbumin. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing.
This vaccine technology was invented by the late Dr. Vincent Tuohy, who was the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. Cleveland Clinic exclusively licensed this technology to Anixa Biosciences. Dr. Tuohy was entitled to a portion of the commercialization revenues received by Cleveland Clinic and also held equity in Anixa.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-japanese-patent-on-breast-cancer-vaccine-technology-302198777.html
SOURCE Anixa Biosciences, Inc.
FAQ
What patent did Anixa Biosciences (ANIX) receive for its breast cancer vaccine technology?
What is the current stage of Anixa Biosciences' (ANIX) breast cancer vaccine clinical trials?
How does Anixa Biosciences' (ANIX) breast cancer vaccine work?
Who invented the breast cancer vaccine technology licensed to Anixa Biosciences (ANIX)?
